SCHEMBL3835945

SCHEMBL3835945

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1Oc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
ALDH1A1 P00352 6/20 0.47
KMT2A Q03164 6/20 0.47
MEN1 O00255 4/20 0.47
GAA P10253 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 1/20 0.44
MDM2 Q00987 1/20 0.44
LMNA P02545 1/20 0.42
RECQL P46063 1/20 0.42
MAT2A P31153 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM4E B2RXH2 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16474394 0.85 MAPT (0.54) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL1265759 0.83 MAPT (0.52) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL2960195 0.83 ALDH1A1 (0.56) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL5650136 0.82 MAPT (0.51) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL2783455 0.81 MAPT (0.50) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL5648517 0.80 ALDH1A1 (0.50) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL1266606 0.80 MAPT (0.49) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL3833709 0.80 MAPT (0.49) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL5652346 0.80 MAPT (0.47) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL5653552 0.80 ALDH1A1 (0.48) MAPTALDH1A1KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592455-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA S.A. (BE) 2009-09-22 US claimed
US-20060025428-A1 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA S.A. (BE) 2006-02-02 US claimed
US-7592455-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA S.A. (BE) 2009-09-22 US disclosed
US-20060025428-A1 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA S.A. (BE) 2006-02-02 US disclosed
EP-1539769-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS Celltech R & D Limited (GB) 2005-06-15 EP disclosed
WO-2004014920-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS CELLTECH R & D LIMITED (GB) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025428-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K6 MAPT 1954/4885ALDH1A1 3847/4885KMT2A 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.